Published in J Virol on August 01, 1999
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One (2009) 3.40
HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology (2006) 3.26
Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol (2003) 2.52
Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J Virol (2000) 2.37
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest (2008) 2.12
A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol (2006) 2.05
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol (2002) 1.97
Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc (2010) 1.87
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol (2003) 1.86
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol (2008) 1.84
Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol (2008) 1.81
The origins of sexually transmitted HIV among men who have sex with men. Sci Transl Med (2010) 1.76
Construction and analysis of an infectious human Immunodeficiency virus type 1 subtype C molecular clone. J Virol (2001) 1.70
Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol (2001) 1.55
Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol (2004) 1.50
Unequal evolutionary rates in the human immunodeficiency virus type 1 (HIV-1) pandemic: the evolutionary rate of HIV-1 slows down when the epidemic rate increases. J Virol (2007) 1.47
HIV: cell binding and entry. Cold Spring Harb Perspect Med (2012) 1.46
Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection. J Virol (2003) 1.44
A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics. Proc Natl Acad Sci U S A (2001) 1.41
High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol (2003) 1.40
Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. J Virol (2000) 1.38
Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers. J Virol (2003) 1.37
N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates. J Virol (2000) 1.32
Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease--indication of an evolving epidemic in West Africa. Retrovirology (2010) 1.25
Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection. J Virol (2000) 1.21
Appreciating HIV type 1 diversity: subtype differences in Env. AIDS Res Hum Retroviruses (2009) 1.17
Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J Virol (2007) 1.14
Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness? J Virol (2003) 1.10
Early evolution of the human immunodeficiency virus type 1 subtype C epidemic in rural Malawi. J Virol (2002) 1.10
Evolution of CCR5 use before and during coreceptor switching. J Virol (2008) 1.09
Exceptional molecular and coreceptor-requirement properties of molecular clones isolated from an Human Immunodeficiency Virus Type-1 subtype C infection. Retrovirology (2008) 1.08
Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND). AIDS Res Ther (2014) 1.08
Clinical significance of HIV-1 coreceptor usage. J Transl Med (2011) 1.07
Faster HIV-1 disease progression among Brazilian individuals recently infected with CXCR4-utilizing strains. PLoS One (2012) 1.05
Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages. J Virol (2005) 1.04
Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. J Virol (2006) 0.98
Infectious simian/human immunodeficiency virus with human immunodeficiency virus type 1 subtype C from an African isolate: rhesus macaque model. J Virol (2001) 0.98
Sequential turnover of human immunodeficiency virus type 1 env throughout the course of infection. J Virol (2006) 0.98
Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization. J Virol (2003) 0.95
CCL2 increases X4-tropic HIV-1 entry into resting CD4+ T cells. J Biol Chem (2008) 0.94
Association of chemokine receptor gene (CCR2-CCR5) haplotypes with acquisition and control of HIV-1 infection in Zambians. Retrovirology (2011) 0.93
Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. Virology (2012) 0.93
Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins. Antimicrob Agents Chemother (2007) 0.92
Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection. PLoS One (2013) 0.92
Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. J Acquir Immune Defic Syndr (2011) 0.88
Multiple independent lineages of HIV-1 persist in breast milk and plasma. AIDS (2011) 0.88
Evaluating immunologic response and clinical deterioration in treatment-naive patients initiating first-line therapies infected with HIV-1 CRF01_AE and subtype B. J Acquir Immune Defic Syndr (2013) 0.86
A group of V3 sequences from human immunodeficiency virus type 1 subtype E non-syncytium-inducing, CCR5-using variants are resistant to positive selection pressure. J Virol (2000) 0.86
Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1. Proc Natl Acad Sci U S A (2003) 0.86
Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection. Retrovirology (2013) 0.86
The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa. J Int AIDS Soc (2012) 0.85
HIV-1 subtype C envelope characteristics associated with divergent rates of chronic disease progression. Retrovirology (2010) 0.83
Bioinformatic analysis of HIV-1 entry and pathogenesis. Curr HIV Res (2014) 0.83
Major histocompatibility complex class II (HLA-DRB and -DQB) allele frequencies in Botswana: association with human immunodeficiency virus type 1 infection. Clin Diagn Lab Immunol (2005) 0.83
Severe anaemia is not associated with HIV-1 env gene characteristics in Malawian children. BMC Infect Dis (2008) 0.83
Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana. J Acquir Immune Defic Syndr (2011) 0.83
Clinical, epidemiological and molecular features of the HIV-1 subtype C and recombinant forms that are circulating in the city of São Paulo, Brazil. Virol J (2012) 0.82
Genetic variation and HIV-associated neurologic disease. Adv Virus Res (2013) 0.81
Defining the fitness of HIV-1 isolates with dual/mixed co-receptor usage. AIDS Res Ther (2015) 0.80
Molecular interaction studies of HIV-1 matrix protein p17 and heparin: identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonists. J Biol Chem (2012) 0.79
Structural and functional studies of CCAAT/enhancer binding sites within the human immunodeficiency virus type 1 subtype C LTR. Biomed Pharmacother (2010) 0.78
Viral tropism and antiretroviral drug resistance in HIV-1 subtype C-infected patients failing highly active antiretroviral therapy in Johannesburg, South Africa. AIDS Res Hum Retroviruses (2013) 0.78
HIV-1 diversity in an antiretroviral treatment naïve cohort from Bushbuckridge, Mpumalanga Province, South Africa. Virol J (2015) 0.78
HIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form. Retrovirology (2010) 0.77
Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc. HIV AIDS (Auckl) (2010) 0.76
Characteristics and spread to the native population of HIV-1 non-B subtypes in two European countries with high migration rate. BMC Infect Dis (2015) 0.76
Coreceptor usage, diversity, and divergence in drug-naive and drug-exposed individuals from Malawi, infected with HIV-1 subtype C for more than 20 years. AIDS Res Hum Retroviruses (2014) 0.75
The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol (1987) 266.90
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol (1986) 36.06
MEGA: Molecular Evolutionary Genetics Analysis software for microcomputers. Comput Appl Biosci (1994) 28.25
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science (1986) 17.33
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 14.64
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 11.37
Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med (1997) 11.01
Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell (1986) 10.70
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (1996) 10.27
Biologic features of HIV-1 that correlate with virulence in the host. Science (1988) 9.06
Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell (1986) 9.01
Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science (1993) 8.49
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol (1992) 7.92
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med (1993) 7.21
Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet (1986) 7.09
Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet (1997) 6.34
Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J Virol (1987) 6.20
The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med (1996) 5.46
A new classification for HIV-1. Nature (1998) 5.30
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol (1997) 5.18
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol (1992) 4.86
An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol (1992) 4.85
Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest (1994) 4.63
Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci U S A (1986) 4.43
Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol (1996) 4.43
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med (1997) 4.21
Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet (1989) 4.19
HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS (1992) 3.91
An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature (1998) 3.69
Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J Virol (1991) 3.46
High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis (1998) 3.46
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44
Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 3.42
The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med (1997) 3.36
HIV entry and tropism: the chemokine receptor connection. AIDS (1997) 3.32
Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology (1997) 3.21
Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis (1992) 3.16
A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med (1998) 3.15
Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med (1997) 3.08
HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J (1997) 2.86
Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation. J Virol (1992) 2.86
Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. J Virol (1991) 2.84
Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet (1997) 2.77
HIV-1 subtype and second-receptor use. Nature (1996) 2.46
Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS (1992) 2.35
Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis (1995) 2.28
V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J Virol (1993) 2.27
Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology (1998) 2.20
Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J Virol (1994) 2.06
Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay. J Virol (1997) 2.04
Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med (1998) 2.01
Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol (1998) 2.01
Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses (1994) 1.99
Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol (1996) 1.94
Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol (1994) 1.85
Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.61
Heterogeneity of HIV-1 and HIV-2. AIDS (1995) 1.41
Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein. Virology (1997) 1.36
Antigenic variation and serotyping of HIV type 1 from four World Health Organization-sponsored HIV vaccine sites. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses (1994) 1.31
Primary subtype C HIV-1 infection in Harare, Zimbabwe. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.22
CCR2-64I allele and genotype association with delayed AIDS progression in African women. University of Nairobi Collaboration for HIV Research. Lancet (1998) 1.12
Correlation between genetic and biological properties of biologically cloned HIV type 1 viruses representing subtypes A, B, and D. AIDS Res Hum Retroviruses (1995) 1.10
Genetic variability of the human immunodeficiency virus: statistical and biological issues. Annu Rev Genet (1994) 1.07
HIV type 1 subtypes, coreceptor usage, and CCR5 polymorphism. AIDS Res Hum Retroviruses (1997) 1.07
CCR2 polymorphism and HIV disease. Swiss HIV Cohort. Nat Med (1998) 1.07
Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. J Infect Dis (1998) 1.07
A model for alignment of Env V1 and V2 hypervariable domains from human and simian immunodeficiency viruses. AIDS Res Hum Retroviruses (1996) 0.96
CCR5/delta(ccr5) heterozygosity: a selective pressure for the syncytium-inducing human immunodeficiency virus type 1 phenotype. NIAID AIDS Clinical Trials Group Protocol 241 Virology Team. J Infect Dis (1998) 0.86
V3 loop sequence analysis of seven HIV type 1 group O isolates phenotyped in peripheral blood mononuclear cells and MT-2 cells. AIDS Res Hum Retroviruses (1996) 0.85
Transient high titers of HIV-1 in plasma and progression of disease. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.79
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A (1992) 16.64
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
X-ray intensifying screens greatly enhance the detection by autoradiography of the radioactive isotopes 32P and 125I. Anal Biochem (1978) 10.28
Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A (1986) 8.45
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Functional mapping of the human visual cortex by magnetic resonance imaging. Science (1991) 6.93
Sexual transmission of HIV. N Engl J Med (1997) 6.84
Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med (2000) 6.72
Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet (1997) 6.34
Complete mutagenesis of the HIV-1 protease. Nature (1989) 5.16
Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS (2000) 4.91
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 4.83
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76
Embryonic epsilon and gamma globin genes of a prosimian primate (Galago crassicaudatus). Nucleotide and amino acid sequences, developmental regulation and phylogenetic footprints. J Mol Biol (1988) 4.75
Unrecognised Mycobacterium tuberculosis bacteraemia among hospital inpatients in less developed countries. Lancet (1999) 4.64
Optic nerve decompression may improve the progressive form of nonarteritic ischemic optic neuropathy. Arch Ophthalmol (1989) 4.48
Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol (2009) 4.40
Promoter-specific trans activation and repression by human cytomegalovirus immediate-early proteins involves common and unique protein domains. J Virol (1990) 4.24
Retrovirus envelope glycoproteins. Curr Top Microbiol Immunol (1990) 4.22
Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol (1997) 4.17
Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell (1997) 3.99
Regulated expression of early and late RNAs and proteins from the human cytomegalovirus immediate-early gene region. J Virol (1989) 3.98
The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol (1994) 3.95
Nucleotide sequence of cloned unintegrated avian sarcoma virus DNA: viral DNA contains direct and inverted repeats similar to those in transposable elements. Proc Natl Acad Sci U S A (1981) 3.82
Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA (2000) 3.81
Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer (1976) 3.79
Locus control regions of mammalian beta-globin gene clusters: combining phylogenetic analyses and experimental results to gain functional insights. Gene (1997) 3.77
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature (1993) 3.73
Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science (1985) 3.69
BEACHES: an observational system for assessing children's eating and physical activity behaviors and associated events. J Appl Behav Anal (1991) 3.61
Phylogenetic footprinting reveals a nuclear protein which binds to silencer sequences in the human gamma and epsilon globin genes. Mol Cell Biol (1992) 3.57
Seven-day recall and other physical activity self-reports in children and adolescents. Med Sci Sports Exerc (1993) 3.57
Maximizing sensitivity and specificity of PCR by pre-amplification heating. Nucleic Acids Res (1991) 3.56
Expression and processing of the AIDS virus reverse transcriptase in Escherichia coli. Science (1987) 3.46
High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis (1998) 3.46
Widespread presence of histologically occult cytomegalovirus. Hum Pathol (1984) 3.45
Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS (1997) 3.42
Transduction of a cellular oncogene: the genesis of Rous sarcoma virus. Proc Natl Acad Sci U S A (1983) 3.41
Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol (1997) 3.38
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS (2001) 3.35
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA (1999) 3.34
The microbicidal mechanisms of human neutrophils and eosinophils. Rev Infect Dis (1981) 3.29
Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A (1996) 3.17
Human cytomegalovirus productively infects primary differentiated macrophages. J Virol (1991) 3.16
The nucleotide sequence of an untranslated but conserved domain at the 3' end of the avian sarcoma virus genome. Nucleic Acids Res (1980) 3.16
Predominant immediate-early transcripts of human cytomegalovirus AD 169. J Virol (1984) 3.15
Trichomonas vaginalis as a cause of urethritis in Malawian men. Sex Transm Dis (1999) 3.12
Mechanism of the luminol-dependent chemiluminescence of human neutrophils. J Immunol (1982) 3.11
Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. J Virol (1999) 3.02
Darwinian evolution in the genealogy of haemoglobin. Nature (1975) 3.00
The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell (1999) 2.97
Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol (1987) 2.97
Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol (1993) 2.96
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo. J Virol (1993) 2.94
Childhood tuberculosis in Malawi: nationwide case-finding and treatment outcomes. Int J Tuberc Lung Dis (2002) 2.90
Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc Natl Acad Sci U S A (1991) 2.80
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol (2001) 2.79
Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet (1992) 2.79
Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology (2001) 2.74
Correlates of physical activity at home in Mexican-American and Anglo-American preschool children. Health Psychol (1993) 2.74
Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study. JAMA (1995) 2.71
Preventing sexual transmission of HIV--new ideas from sub-Saharan Africa. N Engl J Med (2000) 2.67
Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res Hum Retroviruses (1989) 2.62
Sexual transmission of HIV: infectiousness and prevention. AIDS (1999) 2.59
Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci U S A (1994) 2.59
Nucleotide sequence of the 5' noncoding region and part of the gag gene of Rous sarcoma virus. J Virol (1982) 2.53
The leader sequence of the subgenomic mRNA's of Rous sarcoma virus is approximately 390 nucleotides. J Virol (1982) 2.51
Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS (1997) 2.51
Phylogenetic relations of humans and African apes from DNA sequences in the psi eta-globin region. Science (1987) 2.48